BAP1/ASXL1 recruitment and activation for H2A deubiquitination.
about
Substrate specificity of the ubiquitin and Ubl proteasesMolecular architecture of polycomb repressive complexesBAP1, a tumor suppressor gene driving malignant mesothelioma.The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse modelThe emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeuticsUbE2E1/UBCH6 Is a Critical in Vivo E2 for the PRC1-catalyzed Ubiquitination of H2A at Lys-119.H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.The Role of Additional Sex Combs-Like Proteins in Cancer.Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.Histone H2A Monoubiquitination in Neurodevelopmental Disorders.Additional sex combs interacts with enhancer of zeste and trithorax and modulates levels of trimethylation on histone H3K4 and H3K27 during transcription of hsp70.ASXL gain-of-function truncation mutants: defective and dysregulated forms of a natural ribosomal frameshifting product?Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.Ubiquitin recognition of BAP1: understanding its enzymatic function.Deubiquitylating enzymes and drug discovery: emerging opportunities.Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer.USP48 restrains resection by site-specific cleavage of the BRCA1 ubiquitin mark from H2A.ASXL1 c.1934dup;p.Gly646Trpfs*12-a true somatic alteration requiring a new approach.Plant Deubiquitinases and Their Role in the Control of Gene Expression Through Modification of Histones.Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma.Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine.Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1Asxl1 exerts an antiproliferative effect on mouse lung maturation via epigenetic repression of the E2f1-Nmyc axisA bidentate Polycomb Repressive-Deubiquitinase complex is required for efficient activity on nucleosomes
P2860
Q26751372-D4EFD127-B71B-4928-8396-75ABAA7B0130Q33364784-B760453F-0368-4254-831A-4AB49A36A0F4Q33890512-38FB6D37-0E93-4B89-A7E3-D379B779C0ADQ33892323-7D4E557F-EADB-4C1B-97FA-54357E9D6CEEQ37517626-6999FA8F-838D-4723-AF70-E506991A89C5Q38722022-69BA13D5-EF81-45A2-BC9E-B20B370BBBE4Q38906678-6DD45F2E-D107-43F0-930E-ECA7651316ABQ38928350-2AB7B097-3EE7-4F51-9428-747B5CB6037AQ38946185-8D009974-3328-4370-8D52-4C4CA420BA06Q39409765-E3644F06-55D9-4914-AC85-FD9B2B0EF66EQ41712985-ED6C1219-3D7F-4AD8-9C1D-6CE763B06EBFQ42689905-FB6D79E9-8770-43AE-8B3F-5DA0A2ACAFC5Q46856592-A9DBDC29-8503-48BF-BD3A-8F6316B0717DQ47155655-A69BD655-FFE4-4641-9734-63A5E4F03590Q48265884-2A8229A5-FB9A-4397-9996-2DC1CAD04AE6Q48521896-B8647E6C-8714-4B63-BF1D-603692ABD95CQ49185754-43DF7BD1-7C59-4B51-891F-997CF95F2393Q49209843-11FCF460-C38A-4AA7-9E99-267275166372Q49539596-BB0D3A4B-6EF0-4BAE-951C-7F17B7F2524CQ49698247-2279B148-9DBA-4A64-98AA-2E1E20FE0531Q55000725-96271272-69D5-4A35-AB60-E166ED14BBDEQ57804762-F107DA73-B151-4C52-A718-B234A349AA78Q58615781-B7601628-E32F-478F-9A36-A3327666E969Q58695813-C80119A5-0737-432C-8912-028F6CA1E802
P2860
BAP1/ASXL1 recruitment and activation for H2A deubiquitination.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
BAP1/ASXL1 recruitment and activation for H2A deubiquitination.
@en
type
label
BAP1/ASXL1 recruitment and activation for H2A deubiquitination.
@en
prefLabel
BAP1/ASXL1 recruitment and activation for H2A deubiquitination.
@en
P2093
P2860
P356
P1476
BAP1/ASXL1 recruitment and activation for H2A deubiquitination
@en
P2093
Danny D Sahtoe
Reggy Ekkebus
Willem J van Dijk
P2860
P2888
P356
10.1038/NCOMMS10292
P407
P50
P577
2016-01-07T00:00:00Z
P5875
P6179
1011016456